Ofatumumab Pivotal CLL Data to be Presented at ASH

Responses Significantly Correlated to Overall Survival                          

Summary:  Three ofatumumab abstracts have been accepted for presentation at the 
ASH meeting December 6-9, 2008.                                                 

Copenhagen, Denmark; November 10, 2008 - Genmab A/S (OMX: GEN) announced today  
that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for 
presentation at the 50th American Society of Hematology Annual Meeting and      
Exposition (ASH) December 6-9, 2008.  Updated interim efficacy data from the    
pivotal study evaluating ofatumumab to treat two groups of chronic lymphocytic  
leukemia (CLL) patients with an unmet medical need will be presented in an oral 
session.  Headline interim data from the study was announced in July 2008.      

In addition, two abstracts on pre-clinical ofatumumab data have been accepted   
for presentation at poster sessions.  All three ofatumumab abstracts are        
available on the ASH website at www.hematology.org.                             

ASH Sessions                                                                    
Oral Presentation December 8 at 11:45AM PST - Ofatumumab (HuMax-CD20), a Novel  
CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL          
Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory  
Disease:  Results from the Planned Interim Analysis of An International Pivotal 
Trial.                                                                          

Poster I-682 - Complement (C) Activation Followed by Penetration of the Membrane
Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium     
Influx Which Induces Streamers.                                                 

Poster I-683 - Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20    
Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent          
Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA    
Than by RTX.                                                                    

Ofatumumab is an investigational, new generation, human monoclonal antibody that
targets a distinct membrane proximal, small loop epitope (specific binding site)
of the CD20 molecule on the surface of B-cells. Ofatumumab is being developed to
treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse  
large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple    
sclerosis under a co-development and commercialization agreement between Genmab 
and GlaxoSmithKline. It is not yet approved for sale in any country.            

About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for the potential treatment of cancer.        
Genmab's world class discovery, development and manufacturing teams are using   
cutting-edge technology to create and develop products to address unmet medical 
needs.  Our primary goal is to improve the lives of patients who are in urgent  
need of new treatment options.  For more information on Genmab's products and   
technology, visit www.genmab.com.                                               

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. For a     
further discussion of these risks, please refer to the section “Risk Management”
in Genmab's Annual Report, which is available on www.genmab.com.  Genmab does   
not undertake any obligation to update or revise forward looking statements in  
this press release nor to confirm such statements in relation to actual results,
unless required by law.                                                         

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM)   
and UniBody(R) are all trademarks of Genmab A/S.                                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 53/2008                                              

###